4Collaborative Group on Hormonal Factors in Breast Cancer.Breast cancer and hormone replacement therapy:collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer[J].Lancet,1997
5Ray NF,Chan JK,Thamer M,et al.Medical expenditures for the treatment of osteoporotic fracture in the United States in 1995:Report from the National Osteoporosis Foundation[J].J Bone Miner Res,1997,12:24-35.
6Torgerson DJ,Bell-Syer SE.Hormone replacement therapy and prevention of nonvertebral fractures:a meta-analysis of randomized trials[J].JAMA,2001,285:2891-2897.
7Writing Group for the Women Health Initiative Invesigators.Risk and benefits of estrogrn plus progestin in healthy postmenopausal women[J].JAMA,2002,288:321-333.
8The Writing Group for the PEPI Trial.Effects of hormone therapy of bone mineral density[J].J Am Med Assoc,1996,276:1389-1396.
9Stevenson JC.Do we need different galenic forms of oestrogens and progestogens? In Birkh?user MH,Rozenbaum H eds.Menopause[M].Edition Eska,1996.231-235.
10Gallagher JC,Kable WT.Effect of progestin therapy on cortical and trabecular bone:comparison with estrogen[J].Am J Med,1991,90:171-178.
6Geusens P, Dequeker J, Gielen J, et al. Non-linear increase in vertebral density by a synthetic steroid (Org OD14) in established osteoporosis. Maturitas, 1991,13:155-162.
7Zumoff B. 24 h mean plasma concentration declines with age in premenopausal women. J Clin Endocrinol Metab, 1995,80:1429-1430.
8Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int, 1994,4:314-319.
9Rymer JM. Review: The effects of Tibolone. Gynecol Endocrinol, 1998,12:213-220.
10Beming B, Kuijk CV, Kuiper JW, et al. Effects of two doses of Tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone, 1996,19:395-399.
